Trade press release

GEA opens a new chapter for biopharmaceutical separation processes with pharma separator lines aseptic and pure

06 Jul 2021

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

GEA's aseptic separator line offers customers with highly hygienic processes gentle processing of, for example, human and veterinary vaccines, monoclonal antibodies (mAb), e-coli, insulin, starter cultures and probiotic products. (Photo: GEA)

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Line pure is used in applications with varying hygienic requirements such as dietary supplements, therapeutic proteins, pharmaceutical extractions, and extracellular and intracellular enzyme recovery. (Photo: GEA)

Contact

Dr. Michael Golek

Media Relations

GEA Group Aktiengesellschaft

Peter-Müller-Str. 12


40468

Düsseldorf


Germany

+49 211 9136-0

About GEA

GEA is one of the world’s largest suppliers of systems and components to the food, beverage and pharmaceutical industries. The international technology group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components and comprehensive services.

Receive news from GEA

Stay in touch with GEA innovations and stories by signing up for news from GEA.

Need assistance?

We are here to help! With just a few details we will be able to respond to your inquiry.